Search Results for "Pharmac Cost Of Sativex In New Zealand"

02:33 EDT 31st August 2014 | BioPortfolio

Matching Channels

Marginal cost

TASH Biotechnology

Shanghai TASH Biotechnology Co.,Ltd. specializes in peptide development on the basis of high technology. TASH Biotechnology are focusing on custom peptide synthesis, and the research, development...

CaptureSelect

BAC’s CaptureSelect products are affinity ligands and affinity resins created by a proprietary technology based on Camelid-derived single domain antibody fragments for the purification of biop...

CombiCult

CombiCult® is an award winning, combinatorial screening technology that allows scientists to discover new and improved stem cell differentiation protocols. How Combicult® works A short o...

Latin America

Latin America encompasses the Caribbean, South America and Central America. These countries are important players in the biotechnology industry, not only as consumers, but as contributors. The env...

Matching News

Promoting competition key to improving patients’ access to high cost medicines, says PHARMAC

New Zealand’s Pharmaceutical Management Agency, PHARMAC, has announced its intention to test out a contestable fund for high cost medicines for rare disorders, which could be seeking proposals from...

PHARMAC promotes competition to improving patient access to high-cost medicines

PHARMAC has announced its intention to test out a contestable fund for high-cost medicines for rare disorders, which could be seeking proposals from pharmaceutical companies by the end of 2014. Promot...

New Zealand to fund Vidaza and Revlimid

New Zealand’s Pharmaceutical Management Agency PHARMAC says it has approved a proposal for funding two oncology products - azacitidine (Vidaza), lenalidomide (Revlimid) and thalidomide (Thalomid),...

New treatment funded for severe gout in New Zealand

Patients with severe gout will soon have a new treatment option as New Zealand’s Pharmaceutical Management Agency PHARMAC will be funding febuxostat (trade name Adenuric) from June 1, 2014.

Changes to the funding access criteria for some vaccines in New Zealand

New Zealand’s Pharmaceutical Management Agency, PHARMAC, this morning announced changes to the funding access criteria for a number of vaccines.

NZ’s PHARMAC awards sole supply to Eprex to Janssen-Cilag

New Zealand’s Pharmaceutical Management Agency PHARMAC has awarded sole subsidised supply status in the community, and hospital supply status in District Health Boards (DHB) hospitals, to US health...

Multiple sclerosis treatments funding proposal in New Zealand

New Zealand’s Pharmaceutical Management Agency PHARMAC is seeking feedback on a funding proposal involving five treatments for multiple sclerosis (MS), including two new treatments that are not curr...

New Zealand to fund Norgine’s Xifaxan for hepatic encephalopathy

New Zealand Pharmaceutical Management Agency PHARMAC has awarded a tender to Netherlands-headquartered Norgine for sole subsidized supply status and hospital supply status for rifaximin (Xifaxan) that...

Matching PubMed Articles

Does cost drive primary care patients to New Zealand's emergency departments? A systematic review.

The cost of primary care is often stated as a major contributing factor to presentations to New Zealand Emergency Departments. This review sought to determine whether this assumption is supported by t...

Rehabilitation in the New Zealand logging industry.

Work within the New Zealand logging industry is recognised as being dangerous and physically demanding, with relatively high accident and injury frequency rates. As a consequence, the financial cost o...

Sativex(®) (tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical data.

Sativex(®) (nabiximols, USAN name) oromucosal spray contains the two main active constituents of Cannabis sativa, tetrahydrocannabinol and cannabidiol in a 1:1 molecular ratio, and acts as an endocan...

Opioid substitution treatment in New Zealand: a 40 year perspective.

We provide an overview of the history and philosophy of the treatment for opioid dependence, which has been dominated by methadone substitution treatment for the past 40 years in New Zealand. Although...

ST-elevation myocardial infarction: New Zealand Management Guidelines, 2013.

The New Zealand branch of the Cardiac Society of Australia and New Zealand have produced guidelines on the management of acute coronary symptoms since 2005. These have been developed by clinicians thr...

Search Whole site using Google

Loading
Search BioPortfolio:
Advertisement
Advertisement
Advertisement Advertisement